https://www.prnewswire.com/news-releases/neurorx-announces-zyesami-aviptadil-rlf-100-met-the-primary-endpoint-of-its-phase-2b3-clinical-trial-and-also-demonstrated-a-meaningful-benefit-in-survival-from-critical-covid-19-301257291.html
This should be the new standard of care. With a drug that is effective in critical cases, COVID mortality should drop drastically. Offers great protection in the case the virus mutates and becomes resistant to the vaccines. Also a game changer for countries like Brazil getting hit hard.
This should be the new standard of care. With a drug that is effective in critical cases, COVID mortality should drop drastically. Offers great protection in the case the virus mutates and becomes resistant to the vaccines. Also a game changer for countries like Brazil getting hit hard.